Form 8-K - Current report:
SEC Accession No. 0000950170-23-002613
Filing Date
2023-02-13
Accepted
2023-02-13 16:16:28
Documents
12
Period of Report
2023-02-08
Items
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers

Document Format Files

Seq Description Document Type Size
1 8-K evok-20230208.htm   iXBRL 8-K 54387
  Complete submission text file 0000950170-23-002613.txt   168256

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT evok-20230208.xsd EX-101.SCH 2478
3 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT evok-20230208_pre.xml EX-101.PRE 9459
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT evok-20230208_lab.xml EX-101.LAB 12806
6 EXTRACTED XBRL INSTANCE DOCUMENT evok-20230208_htm.xml XML 4534
Mailing Address 420 STEVENS AVENUE SUITE 370 SOLANA BEACH CA 92075
Business Address 420 STEVENS AVENUE SUITE 370 SOLANA BEACH CA 92075 858-345-1494
Evoke Pharma Inc (Filer) CIK: 0001403708 (see all company filings)

EIN.: 208447886 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-36075 | Film No.: 23618696
SIC: 2834 Pharmaceutical Preparations